Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next
NEW YORK, December 31, 2025, 13:58 ET — Regular session Shares of Corcept Therapeutics Incorporated (CORT.O) sank nearly 50% on Wednesday after the U.S. Food and Drug Administration issued a complete response letter for the company’s relacorilant application in hypertension
